Literature DB >> 20352172

Lessons from the major studies in COPD: problems and pitfalls in translating research evidence into practice.

David M G Halpin1.   

Abstract

Translating the growing evidence base on COPD management into practice can be challenging and understanding the strengths and weakness of published studies is crucial. Studies should conform to the standards of CONSORT statement; they should be sufficiently powered, participants should be randomised, there should be assignment concealment, and the outcome measures and analyses should be decided in advance. The interpretation of the results may be affected by age and severity inclusion criteria for the study and the exclusion of patients with co-morbid illnesses. Whether previous medication is continued or stopped can affect the interpretation of the results. Secondary analyses in sub-groups should be viewed with caution unless pre-specified and accommodated in the trial design and power calculations. Real world observational studies may be confounded by non-randomisation of participants but can sometimes yield valuable insights. The way in which the results are presented can influence their interpretation and their magnitude with respect to minimal important differences as well as statistical significance is important. Research help formulate management algorithms but often the questions they address are too specific to allow evidence-based sequencing of therapies.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20352172      PMCID: PMC6602219          DOI: 10.4104/pcrj.2010.00015

Source DB:  PubMed          Journal:  Prim Care Respir J        ISSN: 1471-4418


  7 in total

Review 1.  How to integrate multiple comorbidities in guideline development: article 10 in Integrating and coordinating efforts in COPD guideline development. An official ATS/ERS workshop report.

Authors:  Leonardo M Fabbri; Cynthia Boyd; Piera Boschetto; Klaus F Rabe; A Sonia Buist; Barbara Yawn; Bruce Leff; David M Kent; Holger J Schünemann
Journal:  Proc Am Thorac Soc       Date:  2012-12

2.  Chronic obstructive pulmonary disease self-management activation research trial (COPD-SMART): results of recruitment and baseline patient characteristics.

Authors:  Rennie Russo; David Coultas; Jamile Ashmore; Jennifer Peoples; John Sloan; Bradford E Jackson; Minyong Uhm; Karan P Singh; Steven N Blair; Sejong Bae
Journal:  Contemp Clin Trials       Date:  2015-02-03       Impact factor: 2.226

3.  Tiotropium Respimat(®) vs. HandiHaler(®): real-life usage and TIOSPIR trial generalizability.

Authors:  Sven Schmiedl; Rainald Fischer; Luisa Ibanez; Joan Fortuny; Petra Thürmann; Elena Ballarin; Pili Ferrer; Monica Sabaté; Dominik Rottenkolber; Roman Gerlach; Martin Tauscher; Robert Reynolds; Joerg Hasford; Marietta Rottenkolber
Journal:  Br J Clin Pharmacol       Date:  2015-12-23       Impact factor: 4.335

4.  The prevalence of clinically-relevant comorbid conditions in patients with physician-diagnosed COPD: a cross-sectional study using data from NHANES 1999-2008.

Authors:  Kerry Schnell; Carlos O Weiss; Todd Lee; Jerry A Krishnan; Bruce Leff; Jennifer L Wolff; Cynthia Boyd
Journal:  BMC Pulm Med       Date:  2012-07-09       Impact factor: 3.317

5.  Randomized controlled trials and real-world observational studies in evaluating cardiovascular safety of inhaled bronchodilator therapy in COPD.

Authors:  Peter Kardos; Sally Worsley; Dave Singh; Miguel Román-Rodríguez; David E Newby; Hana Müllerová
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2016-11-25

6.  Exclusion rates in randomized controlled trials of treatments for physical conditions: a systematic review.

Authors:  Jinzhang He; Daniel R Morales; Bruce Guthrie
Journal:  Trials       Date:  2020-02-26       Impact factor: 2.279

7.  Eligibility of real-life patients with COPD for inclusion in trials of inhaled long-acting bronchodilator therapy.

Authors:  David M G Halpin; Marjan Kerkhof; Joan B Soriano; Helga Mikkelsen; David B Price
Journal:  Respir Res       Date:  2016-09-23
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.